Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The impact of peptide surface density on PD-L1 receptor inhibition as a therapeutic strategy for triple negative breast cancer

Journal of Controlled Release(2025)10.1016/j.jconrel.2025.114019Source: DataRank Database

The impact of peptide surface density on PD-L1 receptor inhibition as a therapeutic strategy for triple negative breast cancer is a research paper published in Journal of Controlled Release (2025). On theSindex it has a DataRank of 0.208. It has been cited 3 times.

N/A

0.208DataRank · unranked

Scored on demand from live citation data

3 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 1.47)OA: closedTopics (39)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.208

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (3)

Rudolf G. Abdelmessih ORCID,Debra T. Auguste ORCID,Naira Keshishian

Live enrichment

PubMed:40633770 OpenAlex:https://openalex.org/W4412084793

National Institutes of Health

Grant: 1 R56 CA260972-01A1

National Cancer Institute

FWCI

1.47

Citation Percentile

0.8%

Citation Trend

2026

closedLicense: https://doi.org/10.15223/policy-004

publisherhttps://api.elsevier.com/content/article/PII:S0168365925006406?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0168365925006406?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jconrel.2025.114019

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40633770

Fields of Study

Cancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune ResponsePeptidase Inhibition and AnalysisTriple Negative Breast NeoplasmsImmune Checkpoint InhibitorsMiceAnimalsCell Line, TumorB7-H1 AntigenLiposomesProgrammed Cell Death 1 Receptor

MeSH Terms

Immune Checkpoint InhibitorsAnimalsFemaleHumansLiposomesPeptidesDrug Delivery SystemsCell Line, TumorMiceB7-H1 AntigenProgrammed Cell Death 1 ReceptorTriple Negative Breast Neoplasms

Keywords

Triple-negative breast cancerBreast cancerPeptideCancer researchCancerReceptorChemistryMedicineInternal medicineBiochemistryImmunotherapyPD-L1Targeted Drug DeliveryTnbcPeptide Conjugated LiposomesPeptide Density

Sustainable Development Goals

SDG 0: Good health and well-being

The impact of peptide surface density on PD-L1 receptor inhibition as a therapeutic strategy for triple negative breast cancer

FAIR Checklist

DataRank Breakdown

Authors (3)

Funding (2 grants)

Impact

Open Access

Topics